(Q45384700)

14 December 2017

Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles (English)

1 reference

14 December 2017

0 references

Dominique Fraillery

1

1 reference

14 December 2017

Nathalie Zosso

series ordinal

2

1 reference

14 December 2017

Denise Nardelli-Haefliger

series ordinal

3

1 reference

14 December 2017

language of work or name

English

0 references

publication date

20 February 2009

1 reference

14 December 2017

1 reference

14 December 2017

27

1 reference

14 December 2017

17

1 reference

14 December 2017

2326-2334

1 reference

The causal relation between human papillomavirus and cervical cancer

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Prophylactic human papillomavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Immunologic uniqueness of the genital tract: challenge for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Induction of secretory immunity and memory at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Toll-like receptor control of the adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Effect of toll-like receptor (TLR) agonists on TLR and microbicide expression in uterine and vaginal tissues of the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Do salivary antibodies reliably reflect both mucosal and systemic immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

inferred from DOI database lookup

7 January 2021

based on heuristic

A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.029

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.02.029

1 reference

14 December 2017

1 reference